IASLC Global Survey on Biomarker Testing in Lung Cancer – 2024 Update

Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. By pinpointing specific genetic mutations, it enables multidisciplinary cancer care teams to select the most effective targeted therapies, improving outcomes and minimizing side effects. As cancer care advances toward precision medicine, the importance of biomarker testing in guiding treatment decisions grows significantly; However, the global adoption of comprehensive biomarker testing remains inadequate.

The 2024 Global Survey on Biomarker Testing in Lung Cancer is now closed.

We want to thank all IASLC members, healthcare practitioners, and other stakeholders who participated in our 2024 Global Survey on Biomarker Testing in Lung Cancer. This information will enhance our understanding of the current landscape surrounding biomarker testing in patients diagnosed with lung cancer globally.

2024 Global Biomarker Testing Survey

Dr. Ross Soo, National University Cancer Institute | Singapore

Dr. Ross Soo from the National University Cancer Institute Singapore and Founding Co-Chair of IPTCC emphasizes the importance of biomarker testing in lung cancer care. To improve global practices, he urges healthcare practitioners to complete the survey by March 23, 2024.

Watch Now & Take the Survey!

Dr. Matt Smeltzer, University of Memphis | USA

Join Dr. Matthew Smeltzer, Associate Professor at the University of Memphis and 2024 Biomarker Survey Steering Committee Member, in shaping the future of lung cancer care. Take just 10 minutes to share your valuable insights in the ongoing international survey conducted by IASLC on biomarker testing practices. Your contribution as a researcher, clinician, or advocate is crucial in improving patient outcomes. Take action today and make a difference!

Watch Now & Take the Survey!

Dr. Yasushi Yatabe, Aichi Cancer Center | Japan

Dr. Yasushi Yatabe, from Aichi Cancer Center Hospital in Nagoya, Japan and 2024 Biomarker Testing Survey Steering Committee Member, urges healthcare professionals to participate in the 2024 IASLC Biomarker Survey. Your participation will shape global policies, advance research, improve patient care, and support further resource development. It only takes 10-15 minutes.

Watch Now & Take the Survey!

Biomarkers in Lung Cancer: Barriers to Implementation

LCC in English

Host Dr. Stephen Liu discusses the importance of this survey and some of the barriers to biomarker testing with Dr. Debora Bruno, Dr. Rami Manochakian, and Dr. Matthew Smeltzer.

Listen Now

LCC in Mandarin Chinese

Host Dr. Chunxia Su moderates a discussion in Mandarin about biomarker testing with Dr. Bo Zhu and Dr. Yuan Li.

Listen Now

LCC in Japanese

Host Dr. Misako Nagasaka leads a discussion in Japanese about biomarker testing with Dr. Terufumi Kato and Dr. Masahiro Tsuboi.

Listen Now

LCC in Cantonese Chinese

Host Dr. Sally Lau leads a discussion in Cantonese about barriers to biomarker testing with Dr. Herbert Loong and Dr. Molly Li.

Listen Now

LCC in Spanish

Dr. Narjust Florez discusses the importance of this survey and some of the barriers to biomarker testing in Spanish with Dr. Ivy Riano and Dr. Teresa Gorría.

Listen Now

LCC in Portuguese

Host Dr. Clarissa Mathias leads a discussion in Portuguese about biomarker testing with Dr. Vladmir Lima and Dr. Aknar Calabrich.

Listen Now

LCC in French Canadian

Host Dr. Norman Blais moderates a discussion about biomarker testing with Dr. Arielle Elkrief and Dr. Nicolas Marcoux.

Listen Now

LCC in French

Host Dr. Alfredo Addeo discussed barriers to biomarker testing in French with Dr. Solange Peters and Dr. Maurice Perol.

Listen Now

To better understand barriers to implementation and utilization of biomarker testing globally, the IASLC conducted a survey in 2017 to assess current practices and barriers to uptake of biomarker testing globally. Since the publication of these results in 2018 there have been several therapeutic breakthroughs:

Approvals for advanced lung cancer treatments targeting MET, RET, KRAS, HER2, and NTRK mutations.
Growing regulatory endorsements for ICI-based treatments in stage II-III disease.
The authorization of osimertinib for resectable lung cancer.

With these advancements, it is the ideal time to conduct a new survey to assess the current landscape of biomarker testing globally.

Review the 2017 Survey Results Here

This updated survey will capture the evolving trends in biomarker testing since our last assessment, shed light on the current momentum toward adopting or intensifying NGS testing, and delve into the challenges faced by various providers and health systems. Our objective is to leverage this data to craft a comprehensive resource guide on NGS testing implementation.

This survey is in partnership with the IASLC Partners for Thoracic Cancer Care.